Developer docs
API playgroundTry for free, no card

Search company profiles

InSyBio

Full company profile

uuid0002kr5

Namestring
InSyBio
Legal namestring
InSyBio Group
Websiteurl
insybio.com
Company typeenum
Private
Founded yearint
2013
Descriptiontext

InSyBio is a private biotechnology company founded in 2013 that develops an AI/ML-powered software-as-a-service platform, InSyBio Suite, for multi-omics biomarker discovery and predictive analytics applied to precision medicine and nutrition. The platform integrates genomics, transcriptomics, proteomics, and metabolomics data through proprietary algorithms — including a multi-objective evolutionary optimization method and Adaptive Boosting for class imbalance — packaged as modular tools (BioNets, Interact, Datastore, ncRNASeq, Pipelines, DNASeq, Biomarkers) accessible via web browser without bioinformatics expertise. The company generates revenue through SaaS subscriptions to InSyBio Suite, fixed-price micro-analysis services, a "Pay Upon Success" BioData Analysis Services offering, and professional bioinformatics services, with customers spanning pharmaceutical R&D, academic research institutes, the nutrition and cosmetics industry, and healthcare providers. Beyond the research SaaS, InSyBio has expanded into clinical decision support with a Diagnostics product line that includes PrecisionCHF (75% AUC for 5-year mortality in CHF), PrecisionHCM (97% AUC for short-term outcomes), Precision Chronic Pain Treatment Tools (>82% accuracy across 600+ patients), and Metabolic AI (co-developed with Fitly Health for metabolic syndrome, prediabetes, and Type 2 diabetes). The company operates as InSyBio Group with three legal entities across the UK, Greece, and USA, is supported by five active EU Horizon Europe and MSCA research projects, and has reported working with hundreds of academic and enterprise clients since 2013. The most recent commercial activity includes a 2023 Series A round targeting €2,000,000 led by Loyal VC, a 2023 CPHI Pharma Award for Best Start-Up Initiative in Pharma, and a 2026 selection for Pfizer's Center for Digital Innovation Start4Health ScaleUps Studio programme.

Short descriptiontext

InSyBio is a private biotechnology company offering an AI/ML-powered SaaS platform for multi-omics biomarker discovery and predictive analytics, serving pharmaceutical R&D, academic researchers, the nutrition and cosmetics industry, and healthcare providers across the UK, Greece, and USA.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersNarragansett, United States
HQ citystring
Narragansett
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biomarker discovery software, multi-omics data analysis, precision medicine platform, bioinformatics SaaS, predictive healthcare analytics
Industry3 codes
PRIMARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAANAF
Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics)
SECONDARYHLAAANAH
Patient Stratification, Risk Prediction & Prognostic Modeling
NAICS code3 codes
  • Software Publishers5132
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Medical and Diagnostic Laboratories6215
SIC code2 codes
  • Services-Prepackaged Software7372
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Bioinformatics Software for Precision Medicine and Nutrition
Social media profiles3 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1Software-as-a-Service Subscriptions
TypeSubscription Recurring
Description

SaaS platform subscriptions to InSyBio Suite with tiered pricing plans. Users can purchase short-term access passes or fixed-price micro-analysis services. Revenue is generated through recurring subscription fees with annual and monthly billing options. The company also offers a free one-month trial to drive conversion to paid plans.

insybio.com
2Professional Bioinformatics Services
TypeProfessional Services
Description

Bespoke bioinformatics and software services for academic research, pharma industry, and nutrition/cosmetics industry. Includes 'Pay Upon Success' BioData Analysis Services where fees are contingent on successful outcomes. Fixed-price micro-analysis services also offered.

insybio.com
Marketing channels9 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Pricing details2 tiers
1Free one-month trial license of InSyBio Suite
ModelFreemiumBilling cadenceMonthly
Notes

Fully functional trial; use your own datasets; requires verification (1-2 business days). After trial, conversion to paid subscription.

insybio.com
2InSyBio Suite Paid Subscription Tiers
ModelSubscriptionBilling cadenceAnnual
Notes

Specific pricing tiers are not publicly disclosed on the website. InSyBio Suite Pricing page exists but exact figures are quote-based.

insybio.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 4 records shown
1InSyBio Suite
Description

AI-powered SaaS platform for multi-omics data analysis, biomarker discovery, and predictive analytics in precision medicine and nutrition.

insybio.com
+3 more records
Core offering1 text field

InSyBio develops and sells InSyBio Suite, a cloud-based SaaS platform that integrates multi-omics and clinical data for biomarker discovery and predictive analytics in precision medicine and nutrition. The platform is designed for non-bioinformatics experts and combines proprietary machine learning algorithms with specialized modules for protein interaction analysis, RNA/DNA sequencing, biological network reconstruction, and automated pipelines. InSyBio also offers standalone diagnostic tools (Precision Chronic Pain, PrecisionCHF, PrecisionHCM, Metabolic AI) and bespoke bioinformatics services on a pay-upon-success basis.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • At least 10% increase in predictive accuracy for biomarker discovery tasks compared to traditional approaches
+5 more records
Product overview1 text field

InSyBio is a biotechnology company offering a unified software-as-a-service (SaaS) platform called InSyBio Suite for precision medicine and nutrition through biomarker discovery and predictive analytics. The platform comprises multiple specialized modules: InSyBio BioNets (biological network analysis for biomarker discovery), InSyBio Interact (protein-protein interaction analysis with 2M+ interaction database), InSyBio Datastore (biological data storage), InSyBio ncRNASeq (non-coding RNA and single-cell RNA sequencing analysis), InSyBio Pipelines (automated biomarker discovery workflows), InSyBio DNASeq (DNA sequencing analysis), and InSyBio Biomarkers (multi-omics predictive analytics using machine learning). The company also provides diagnostic tools including InSyBio Precision Chronic Pain Treatment Tools, PrecisionCHF, PrecisionHCM, and Metabolic AI (co-developed with Fitly Health), alongside open-source tools (Virtuous Multi-Taste, GENA, MEvA-X, Scaffold Design Optimization) developed through EU Horizon projects. Solutions are offered via subscription licensing (InSyBio Suite), free trials, and pay-upon-success service models.

Product and service11 records
1InSyBio Suite
CategoryCore SaaS Platform
Description

Cloud-based SaaS machine learning platform that comprehensively integrates multi-omics and clinical data for biomarker discovery and predictive analytics, designed for non-bioinformatics experts and unifying multiple specialized tools under one subscription.

2InSyBio Precision Chronic Pain Treatment Tools
CategoryDiagnostic Tool
Description

AI-powered diagnostic tools that stratify chronic pain patients and identify the best non-opioid treatment formulations (Topical Analgesics, Salonpas, Kailo, Upatras Osteoarthritis) based on demographics, clinical characteristics, and questionnaire responses. Co-developed with Clarity Science LLC using OPERA study data.

3PrecisionCHF Tool
CategoryDiagnostic Tool
Description

Outcome prediction and precision treatment tool for congestive heart failure patients. Predicts 5-year mortality with 75% AUC and recommends therapeutic protocol optimizations to reduce patient risk.

4PrecisionHCM Tool
CategoryDiagnostic Tool
Description

Outcome prediction and precision treatment tool for hypertrophic cardiomyopathy patients. Predicts short-term mortality (until discharge) with 97% AUC and recommends medication plan optimizations.

5Metabolic AI
CategoryPrecision Nutrition Program
Description

Precision nutrition program for metabolic syndrome, prediabetes, and Type 2 diabetes, co-developed with Fitly Health. Powered by gut microbiome analysis, predictive generative AI, precision nutrition tracking, and virtual coaching for personalized metabolic health management.

6Pay Upon Success BioData Analysis Services
CategoryProfessional Bioinformatics Service
Description

Bespoke bioinformatics and data analysis services offered on a contingency basis, where fees are contingent on successful outcomes. Includes fixed-price micro-analysis services and short-term access passes for specific analyses, targeting academic research, pharma industry, and nutrition/cosmetics customers.

7InSyBio Personalization Test
CategoryPrecision Medicine Service
Description

Service for building personalized tests faster, more accurately, and using low sample size studies, supporting precision medicine applications.

8InSyBio Cosmetics
CategoryDomain-Specific Tool
Description

Domain-specific biomarker discovery and analysis tools tailored for the cosmetics industry, supporting efficacy testing and personalization for nutrition and cosmetics sector customers.

9Virtuous Multi-Taste Predictor
CategoryOpen Source Tool
Description

Multi-class predictor for taste sensations (sweet, umami, bitter, other) based on a multi-objective machine learning method. Predicts taste of chemical compounds based on their physiochemical properties. Developed within the VIRTUOUS Horizon 2020 project.

10Scaffold Design Optimization and Prediction Tool
CategoryOpen Source Tool
Description

Tool combining genetic algorithms with machine learning models to support scaffold design optimization and prediction for biomedical and materials engineering applications. Compatible with multiple bioreactor designs via universal scaffold design parameters. Developed within the OSTEONET Horizon Europe project.

11Experimental Design Optimization and Prediction Tool
CategoryOpen Source Tool
Description

Tool integrating genetic algorithms with machine learning models to optimize and predict bioreactor configurations for enhanced cell vitality and production. Operated with datasets from two different bioreactors and static control environments (139 samples total). Developed within the REGENERATION Horizon Europe project.

Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership11 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-01
Description

Selected for the Start4Health ScaleUps Studio Programme led by Pfizer CDI. Participation includes preparation workshops with Found.ation, introductory sessions with Pfizer's Embedded Innovation team, and a Solution Exploration Workshop with Pfizer business units. The track is designed for mature startups to co-design potential collaboration projects with Pfizer. Scheduled February-March 2026.

2Patras Science Park
Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2026-03-01
Description

InSyBio accepted into the A4SUSTINNO accelerator programme organized by Patras Science Park in collaboration with Point of Synergy. The programme offers at least 40 hours of educational content, 4 hours of personalized support per company, and 2 presentation events. Supports digital technology startups in Greece's innovation ecosystem.

insybio.com
3Syndesis Health
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-09-19
Description

Strategic partnership to leverage clinical and genomic data on Syntium, Syndesis' data platform of global healthcare data, to accelerate R&D in cardiovascular health, oncology, and rare diseases. The partnership enabled co-development of PrecisionCHF and PrecisionHCM AI tools using Syntium's curated clinical datasets. The collaboration demonstrated the value of combining curated clinical data with AI-driven biomarker discovery technology.

insybio.com
4Fitly Health
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-09-05
Description

Partnership to create the world's first Metabolic AI precision nutrition program for metabolic syndrome, prediabetes, and Type 2 diabetes. InSyBio provides gut microbiome analysis and predictive analytics; Fitly Health provides SmartPlate technology, virtual coaching, and precision nutrition tracking. The program includes financial incentives for patient adherence over a 12-month period.

insybio.com
5GALATEA Horizon Europe Project Consortium
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-01-01
Description

GALATEA Horizon Europe Project focused on advancing innovation in digital health through AI-driven digital twin technologies for personalised infant nutrition. InSyBio participated in midterm meeting in Athens (March 2026) at Athena Research Center. Consortium brings together expertise from multiple disciplines across Europe.

insybio.com
6OSTEONET Project Consortium (EU Horizon Europe MSCA)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-01-01
Description

Horizon Europe MSCA Staff Exchange project (grant agreement No. 101086329) developing reliable and sustainable 3D in vitro models of healthy and aged bone tissue for preclinical drug screening. Consortium includes academic and industry partners across Europe. Led to bioreactor characterization and tissue engineering publications.

insybio.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-01-01
Description

Horizon Europe MSCA Staff Exchange project (grant agreement No. 101131255) focused on PeRsonalised treatmEnts and pain manaGEmeNt for rEpaiR of Aged bone Tissue with Quantum Molecular Resonance (QMR). Partners include Dalle Molle Institute for AI, National Research Council, Cellex S.R.L., and Athena Research Center. Led to bone regeneration computational methods publication.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-03-02
Description

Collaboration to develop machine learning-based tools for predicting chronic pain patient response to non-opioid topical analgesic treatments. The OPERA study (Optimizing Patient Experience and Response to Topical Analgesics) provided clinical data. Developed tools for Topical Analgesics, Salonpas, Kailo, and Upatras Osteoarthritis formulations.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2019-11-26
Description

Strategic partnership to pioneer precision medicine innovation in clinical trials. Axios Investments Corporation facilitated the partnership. Aims to transform the clinical trial process through biomarker discovery and patient stratification.

10VIRTUOUS Project Consortium (EU Horizon 2020 RISE)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-01-01
Description

Marie Skłodowska-Curie Research and Innovation Staff Exchange project to develop a virtual tongue for taste prediction. Partners include Politecnico di Torino (Italy), Dalle Molle Institute for Artificial Intelligence (Switzerland), Industrial Systems Institute (Greece), and 4 other European consortium members. Led to Virtuous Multi-Taste predictor and Taste Receptor interactome publications.

insybio.com
Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2017-11-24
Description

InSyBio joined the International Accelerator program in Austin, Texas to access the US biotechnology market. Participated in Demo Day in October 2019 showcasing breakthrough technology to the Texas investment community.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Cloud platform for life sciences R&D including molecular biology, multi-omics, and lab informatics. Targets the same biotech/pharma R&D audience as InSyBio with a broader lab-notebook-to-analytics stack, but is more focused on experimental workflows than biomarker discovery.

TypeEmerging player
Description

AI-driven precision medicine company applying causal machine learning to multi-omics and clinical data for pharma R&D. Closely comparable to InSyBio Biomarkers in using ML on omics data for outcome prediction, with a more focused oncology/PARP inhibitor track record.

TypeEmerging player
Description

Genomics and real-world data platform for pharma R&D and precision medicine, with strong European footprint similar to InSyBio's. Offers comparable genomic data management and analysis tooling for biomarker discovery and clinical research.

TypeBroad incumbent
Description

Division of QIAGEN offering industry-standard bioinformatics tools (Ingenuity Pathway Analysis, QIAseq) for omics interpretation and biomarker discovery. Provides overlapping capabilities to InSyBio's suite but as part of QIAGEN's broader sample-prep-to-interpretation portfolio for pharma and academic customers.

TypeEmerging player
Description

Provides bioinformatics software and clinical genomics interpretation services for research and diagnostics. Overlaps with InSyBio in multi-omics analytics and clinical variant interpretation, with meaningful presence in India and emerging markets.

TypeBroad incumbent
Description

Dominant sequencing platform vendor that has expanded into bioinformatics via DRAGEN and BaseSpace Sequence Hub. Overlaps with InSyBio's DNA-seq and multi-omics analysis capabilities, but as a broader sequencing-instruments-and-software incumbent rather than a focused SaaS play.

TypeRegional player
Description

AI-based clinical genomic interpretation platform for hereditary disease and oncology. Comparable to InSyBio Diagnostics' clinical decision support positioning, with primary commercial footprint in North America rather than EU/US dual presence.

TypeDirect peer
Description

Cloud-based bioinformatics platform for genomics and multi-omics data analysis, serving pharma R&D, clinical research, and diagnostic labs. Closely matches InSyBio's positioning as a SaaS environment for biomarker discovery and omics pipelines.

TypeDirect peer
Description

Clinical genomics and multi-omics informatics platform supporting diagnostic interpretation and pharma research workflows. Directly comparable to InSyBio Diagnostics and InSyBio Suite as an integrated environment for variant interpretation, biomarker discovery, and clinical decision support.

TypeDirect peer
Description

AI-driven genomics and multi-omics clinical analysis platform serving hospitals, pharma, and research centers — directly comparable to InSyBio in offering SaaS-based biomarker discovery and clinical decision support across multi-omics data, with a more mature enterprise footprint and listed on Nasdaq.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI capability9 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature12 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

InSyBio

Bioinformatics Software for Precision Medicine and Nutritioninsybio.com

InSyBio is a private biotechnology company offering an AI/ML-powered SaaS platform for multi-omics biomarker discovery and predictive analytics, serving pharmaceutical R&D, academic researchers, the nutrition and cosmetics industry, and healthcare providers across the UK, Greece, and USA.

What InSyBio does

InSyBio is a private biotechnology company founded in 2013 that develops an AI/ML-powered software-as-a-service platform, InSyBio Suite, for multi-omics biomarker discovery and predictive analytics applied to precision medicine and nutrition. The platform integrates genomics, transcriptomics, proteomics, and metabolomics data through proprietary algorithms — including a multi-objective evolutionary optimization method and Adaptive Boosting for class imbalance — packaged as modular tools (BioNets, Interact, Datastore, ncRNASeq, Pipelines, DNASeq, Biomarkers) accessible via web browser without bioinformatics expertise. The company generates revenue through SaaS subscriptions to InSyBio Suite, fixed-price micro-analysis services, a "Pay Upon Success" BioData Analysis Services offering, and professional bioinformatics services, with customers spanning pharmaceutical R&D, academic research institutes, the nutrition and cosmetics industry, and healthcare providers. Beyond the research SaaS, InSyBio has expanded into clinical decision support with a Diagnostics product line that includes PrecisionCHF (75% AUC for 5-year mortality in CHF), PrecisionHCM (97% AUC for short-term outcomes), Precision Chronic Pain Treatment Tools (>82% accuracy across 600+ patients), and Metabolic AI (co-developed with Fitly Health for metabolic syndrome, prediabetes, and Type 2 diabetes). The company operates as InSyBio Group with three legal entities across the UK, Greece, and USA, is supported by five active EU Horizon Europe and MSCA research projects, and has reported working with hundreds of academic and enterprise clients since 2013. The most recent commercial activity includes a 2023 Series A round targeting €2,000,000 led by Loyal VC, a 2023 CPHI Pharma Award for Best Start-Up Initiative in Pharma, and a 2026 selection for Pfizer's Center for Digital Innovation Start4Health ScaleUps Studio programme.

InSyBio firmographics

Firmographics
Name
InSyBio
Legal name
InSyBio Group
Website
https://insybio.com
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
1–10 employees
Short description
InSyBio is a private biotechnology company offering an AI/ML-powered SaaS platform for multi-omics biomarker discovery and predictive analytics, serving pharmaceutical R&D, academic researchers, the nutrition and cosmetics industry, and healthcare providers across the UK, Greece, and USA.
Ownership category
akta.pro rank

InSyBio industry classification

Industry
Product category
Bioinformatics Software for Precision Medicine and Nutrition
NAICS
Software Publishers (5132), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical and Diagnostic Laboratories (6215)
SIC
Services-Prepackaged Software (7372), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAANAF
Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics)
SECONDARYHLAAANAH
Patient Stratification, Risk Prediction & Prognostic Modeling

Keywords

  • Biomarker discovery software
  • Multi-omics data analysis
  • Precision medicine platform
  • Bioinformatics SaaS
  • Predictive healthcare analytics

Where InSyBio is headquartered

Location

Headquarters

HQ city
Narragansett
HQ country
United States
HQ region
North America

Offices4 records

Markets served

InSyBio business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Software-as-a-Service Subscriptions: SaaS platform subscriptions to InSyBio Suite with tiered pricing plans. Users can purchase short-term access passes or fixed-price micro-analysis services. Revenue is generated through recurring subscription fees with annual and monthly billing options. The company also offers a free one-month trial to drive conversion to paid plans.
  2. Professional Bioinformatics Services: Bespoke bioinformatics and software services for academic research, pharma industry, and nutrition/cosmetics industry. Includes 'Pay Upon Success' BioData Analysis Services where fees are contingent on successful outcomes. Fixed-price micro-analysis services also offered.

Pricing tiers

ModelBillingPrice
FreemiumMonthlyFree one-month trial license of InSyBio Suite
SubscriptionAnnualInSyBio Suite Paid Subscription Tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels9 records

InSyBio product offering

Product offering

Core offering

InSyBio develops and sells InSyBio Suite, a cloud-based SaaS platform that integrates multi-omics and clinical data for biomarker discovery and predictive analytics in precision medicine and nutrition. The platform is designed for non-bioinformatics experts and combines proprietary machine learning algorithms with specialized modules for protein interaction analysis, RNA/DNA sequencing, biological network reconstruction, and automated pipelines. InSyBio also offers standalone diagnostic tools (Precision Chronic Pain, PrecisionCHF, PrecisionHCM, Metabolic AI) and bespoke bioinformatics services on a pay-upon-success basis.

Product overview

InSyBio is a biotechnology company offering a unified software-as-a-service (SaaS) platform called InSyBio Suite for precision medicine and nutrition through biomarker discovery and predictive analytics. The platform comprises multiple specialized modules: InSyBio BioNets (biological network analysis for biomarker discovery), InSyBio Interact (protein-protein interaction analysis with 2M+ interaction database), InSyBio Datastore (biological data storage), InSyBio ncRNASeq (non-coding RNA and single-cell RNA sequencing analysis), InSyBio Pipelines (automated biomarker discovery workflows), InSyBio DNASeq (DNA sequencing analysis), and InSyBio Biomarkers (multi-omics predictive analytics using machine learning). The company also provides diagnostic tools including InSyBio Precision Chronic Pain Treatment Tools, PrecisionCHF, PrecisionHCM, and Metabolic AI (co-developed with Fitly Health), alongside open-source tools (Virtuous Multi-Taste, GENA, MEvA-X, Scaffold Design Optimization) developed through EU Horizon projects. Solutions are offered via subscription licensing (InSyBio Suite), free trials, and pay-upon-success service models.

Differentiator

Problem solved

Functional benefit

Brands

  • InSyBio Suite: AI-powered SaaS platform for multi-omics data analysis, biomarker discovery, and predictive analytics in precision medicine and nutrition.
  • InSyBio Diagnostics
  • InSyBio Precision Chronic Pain Treatment Tools
  • Metabolic AI

Products and services

  • InSyBio Suite Cloud-based SaaS machine learning platform that comprehensively integrates multi-omics and clinical data for biomarker discovery and predictive analytics, designed for non-bioinformatics experts and unifying multiple specialized tools under one subscription.
  • InSyBio Precision Chronic Pain Treatment Tools AI-powered diagnostic tools that stratify chronic pain patients and identify the best non-opioid treatment formulations (Topical Analgesics, Salonpas, Kailo, Upatras Osteoarthritis) based on demographics, clinical characteristics, and questionnaire responses. Co-developed with Clarity Science LLC using OPERA study data.
  • PrecisionCHF Tool Outcome prediction and precision treatment tool for congestive heart failure patients. Predicts 5-year mortality with 75% AUC and recommends therapeutic protocol optimizations to reduce patient risk.
  • PrecisionHCM Tool Outcome prediction and precision treatment tool for hypertrophic cardiomyopathy patients. Predicts short-term mortality (until discharge) with 97% AUC and recommends medication plan optimizations.
  • Metabolic AI Precision nutrition program for metabolic syndrome, prediabetes, and Type 2 diabetes, co-developed with Fitly Health. Powered by gut microbiome analysis, predictive generative AI, precision nutrition tracking, and virtual coaching for personalized metabolic health management.
  • Pay Upon Success BioData Analysis Services Bespoke bioinformatics and data analysis services offered on a contingency basis, where fees are contingent on successful outcomes. Includes fixed-price micro-analysis services and short-term access passes for specific analyses, targeting academic research, pharma industry, and nutrition/cosmetics customers.
  • InSyBio Personalization Test Service for building personalized tests faster, more accurately, and using low sample size studies, supporting precision medicine applications.
  • InSyBio Cosmetics Domain-specific biomarker discovery and analysis tools tailored for the cosmetics industry, supporting efficacy testing and personalization for nutrition and cosmetics sector customers.
  • Virtuous Multi-Taste Predictor Multi-class predictor for taste sensations (sweet, umami, bitter, other) based on a multi-objective machine learning method. Predicts taste of chemical compounds based on their physiochemical properties. Developed within the VIRTUOUS Horizon 2020 project.
  • Scaffold Design Optimization and Prediction Tool Tool combining genetic algorithms with machine learning models to support scaffold design optimization and prediction for biomedical and materials engineering applications. Compatible with multiple bioreactor designs via universal scaffold design parameters. Developed within the OSTEONET Horizon Europe project.
  • Experimental Design Optimization and Prediction Tool Tool integrating genetic algorithms with machine learning models to optimize and predict bioreactor configurations for enhanced cell vitality and production. Operated with datasets from two different bioreactors and static control environments (139 samples total). Developed within the REGENERATION Horizon Europe project.

Quantifiable outcome

  • At least 10% increase in predictive accuracy for biomarker discovery tasks compared to traditional approaches
  • +5 more outcomes

Companies that use InSyBio

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles4 records

InSyBio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability9 records

Feature12 records

InSyBio partnerships and signals

Strategic signal

Partnerships

Eleven partnerships are on record, tiered core and minor.

  • Pfizer Center for Digital Innovation (CDI)coreStrategic or Co-development Partner · 1 March 2026Selected for the Start4Health ScaleUps Studio Programme led by Pfizer CDI. Participation includes preparation workshops with Found.ation, introductory sessions with Pfizer's Embedded Innovation team, and a Solution Exploration Workshop with Pfizer business units. The track is designed for mature startups to co-design potential collaboration projects with Pfizer. Scheduled February-March 2026.
  • Patras Science ParkminorGTM or Marketing Partner · 1 March 2026InSyBio accepted into the A4SUSTINNO accelerator programme organized by Patras Science Park in collaboration with Point of Synergy. The programme offers at least 40 hours of educational content, 4 hours of personalized support per company, and 2 presentation events. Supports digital technology startups in Greece's innovation ecosystem.
  • Syndesis HealthcoreStrategic or Co-development Partner · 19 September 2023Strategic partnership to leverage clinical and genomic data on Syntium, Syndesis' data platform of global healthcare data, to accelerate R&D in cardiovascular health, oncology, and rare diseases. The partnership enabled co-development of PrecisionCHF and PrecisionHCM AI tools using Syntium's curated clinical datasets. The collaboration demonstrated the value of combining curated clinical data with AI-driven biomarker discovery technology.
  • Fitly HealthcoreStrategic or Co-development Partner · 5 September 2023Partnership to create the world's first Metabolic AI precision nutrition program for metabolic syndrome, prediabetes, and Type 2 diabetes. InSyBio provides gut microbiome analysis and predictive analytics; Fitly Health provides SmartPlate technology, virtual coaching, and precision nutrition tracking. The program includes financial incentives for patient adherence over a 12-month period.
  • GALATEA Horizon Europe Project ConsortiumcoreStrategic or Co-development Partner · 1 January 2023GALATEA Horizon Europe Project focused on advancing innovation in digital health through AI-driven digital twin technologies for personalised infant nutrition. InSyBio participated in midterm meeting in Athens (March 2026) at Athena Research Center. Consortium brings together expertise from multiple disciplines across Europe.
  • OSTEONET Project Consortium (EU Horizon Europe MSCA)coreStrategic or Co-development Partner · 1 January 2022Horizon Europe MSCA Staff Exchange project (grant agreement No. 101086329) developing reliable and sustainable 3D in vitro models of healthy and aged bone tissue for preclinical drug screening. Consortium includes academic and industry partners across Europe. Led to bioreactor characterization and tissue engineering publications.
  • REGENERATION Project Consortium (EU Horizon Europe MSCA)coreStrategic or Co-development Partner · 1 January 2022Horizon Europe MSCA Staff Exchange project (grant agreement No. 101131255) focused on PeRsonalised treatmEnts and pain manaGEmeNt for rEpaiR of Aged bone Tissue with Quantum Molecular Resonance (QMR). Partners include Dalle Molle Institute for AI, National Research Council, Cellex S.R.L., and Athena Research Center. Led to bone regeneration computational methods publication.
  • Clarity Science LLCcoreStrategic or Co-development Partner · 2 March 2021Collaboration to develop machine learning-based tools for predicting chronic pain patient response to non-opioid topical analgesic treatments. The OPERA study (Optimizing Patient Experience and Response to Topical Analgesics) provided clinical data. Developed tools for Topical Analgesics, Salonpas, Kailo, and Upatras Osteoarthritis formulations.
  • JSS Medical Research Inc.minorStrategic or Co-development Partner · 26 November 2019Strategic partnership to pioneer precision medicine innovation in clinical trials. Axios Investments Corporation facilitated the partnership. Aims to transform the clinical trial process through biomarker discovery and patient stratification.
  • VIRTUOUS Project Consortium (EU Horizon 2020 RISE)coreStrategic or Co-development Partner · 1 January 2019Marie Skłodowska-Curie Research and Innovation Staff Exchange project to develop a virtual tongue for taste prediction. Partners include Politecnico di Torino (Italy), Dalle Molle Institute for Artificial Intelligence (Switzerland), Industrial Systems Institute (Greece), and 4 other European consortium members. Led to Virtuous Multi-Taste predictor and Taste Receptor interactome publications.
  • International AcceleratorminorGTM or Marketing Partner · 24 November 2017InSyBio joined the International Accelerator program in Austin, Texas to access the US biotechnology market. Participated in Demo Day in October 2019 showcasing breakthrough technology to the Texas investment community.

Scale indicators12 records

Recent moves6 records

Expansion highlights7 records

InSyBio competitors and assessment

Company assessment

Emerging players

  • Benchling: Cloud platform for life sciences R&D including molecular biology, multi-omics, and lab informatics. Targets the same biotech/pharma R&D audience as InSyBio with a broader lab-notebook-to-analytics stack, but is more focused on experimental workflows than biomarker discovery.
  • GNS Healthcare: AI-driven precision medicine company applying causal machine learning to multi-omics and clinical data for pharma R&D. Closely comparable to InSyBio Biomarkers in using ML on omics data for outcome prediction, with a more focused oncology/PARP inhibitor track record.
  • BC Platforms: Genomics and real-world data platform for pharma R&D and precision medicine, with strong European footprint similar to InSyBio's. Offers comparable genomic data management and analysis tooling for biomarker discovery and clinical research.
  • Strand Life Sciences: Provides bioinformatics software and clinical genomics interpretation services for research and diagnostics. Overlaps with InSyBio in multi-omics analytics and clinical variant interpretation, with meaningful presence in India and emerging markets.

Broad incumbents

  • QIAGEN Digital Insights: Division of QIAGEN offering industry-standard bioinformatics tools (Ingenuity Pathway Analysis, QIAseq) for omics interpretation and biomarker discovery. Provides overlapping capabilities to InSyBio's suite but as part of QIAGEN's broader sample-prep-to-interpretation portfolio for pharma and academic customers.
  • Illumina (DRAGEN / BaseSpace): Dominant sequencing platform vendor that has expanded into bioinformatics via DRAGEN and BaseSpace Sequence Hub. Overlaps with InSyBio's DNA-seq and multi-omics analysis capabilities, but as a broader sequencing-instruments-and-software incumbent rather than a focused SaaS play.

Regional players

  • Fabric Genomics (formerly Omicia): AI-based clinical genomic interpretation platform for hereditary disease and oncology. Comparable to InSyBio Diagnostics' clinical decision support positioning, with primary commercial footprint in North America rather than EU/US dual presence.

Direct peers

  • DNAnexus: Cloud-based bioinformatics platform for genomics and multi-omics data analysis, serving pharma R&D, clinical research, and diagnostic labs. Closely matches InSyBio's positioning as a SaaS environment for biomarker discovery and omics pipelines.
  • Velsera (formerly PierianDx / Seven Bridges): Clinical genomics and multi-omics informatics platform supporting diagnostic interpretation and pharma research workflows. Directly comparable to InSyBio Diagnostics and InSyBio Suite as an integrated environment for variant interpretation, biomarker discovery, and clinical decision support.
  • SOPHiA GENETICS: AI-driven genomics and multi-omics clinical analysis platform serving hospitals, pharma, and research centers — directly comparable to InSyBio in offering SaaS-based biomarker discovery and clinical decision support across multi-omics data, with a more mature enterprise footprint and listed on Nasdaq.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

InSyBio social profiles

Digital presence

InSyBio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

InSyBio leadership team

Management profile

Number of profiles

Profiles8 records

InSyBio funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

InSyBio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about InSyBio

What does InSyBio do?

InSyBio develops and sells InSyBio Suite, a cloud-based SaaS platform that integrates multi-omics and clinical data for biomarker discovery and predictive analytics in precision medicine and nutrition. The platform is designed for non-bioinformatics experts and combines proprietary machine learning algorithms with specialized modules for protein interaction analysis, RNA/DNA sequencing, biological network reconstruction, and automated pipelines. InSyBio also offers standalone diagnostic tools (Precision Chronic Pain, PrecisionCHF, PrecisionHCM, Metabolic AI) and bespoke bioinformatics services on a pay-upon-success basis.

Is InSyBio a public or private company?

InSyBio is a private company. It is classified as venture growth investor backed and is currently operating.

When was InSyBio founded?

InSyBio was founded in 2013. It employs 1 to 10 people.

Where is InSyBio based?

InSyBio is headquartered in Narragansett, United States, in the North America region.

How does InSyBio make money?

Two revenue lines are on record. Software-as-a-Service Subscriptions are the primary driver. The others are professional Bioinformatics Services.

Who are InSyBio's main competitors?

Emerging players on record are Benchling, GNS Healthcare, BC Platforms and Strand Life Sciences. Broad incumbents are QIAGEN Digital Insights and Illumina (DRAGEN / BaseSpace). Fabric Genomics (formerly Omicia) is listed as a regional player. Direct peers are DNAnexus, Velsera (formerly PierianDx / Seven Bridges) and SOPHiA GENETICS.

Does InSyBio have an API?

No public API is recorded for InSyBio.

What industry is InSyBio in?

InSyBio's product category is Bioinformatics Software for Precision Medicine and Nutrition. Its primary akta.pro industry code is HLAGAJAD, Bioinformatics & Multi-omics Analysis Software, with a secondary code of HLAAANAF, Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics). Its NAICS code is 5132 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales